IMMUNEERING CORP - CLASS A (IMRX) Institutional Ownership Changes & 13F Activity

IMMUNEERING CORP - CLASS A (IMRX) institutional ownership data tracks hedge funds, asset managers, and other institutional investors based on recent SEC 13F filings (Q1 2026). This page analyzes institutional buying and selling activity, new holdings, and sold-out positions among tracked filers. Notable filers include Renaissance Technologies LLC.

Portfolio quarterNameTypeQuantityRemainingReported stock balance
Q1 2026Renaissance Technologies LLCSell-79,42572,875$384,051
Q4 2025Renaissance Technologies LLCBuy117,300152,300$1,002,134
Q3 2025Renaissance Technologies LLCBuy16,80035,000$245,000
Q2 2025Renaissance Technologies LLCSell-330,90018,200$61,334
Q2 2024Renaissance Technologies LLCBuy323,563349,100$446,848
Q2 2022Renaissance Technologies LLCSell-32,06325,537$138
Q1 2022Renaissance Technologies LLCBuy57,60057,600$373

Frequently asked questions about IMRX activity

  • Which institutional owners are buying IMRX?

    Institutional owners buying IMRX include investors who have either initiated new positions or increased their existing holdings based on recent SEC 13F filings. The activity table above highlights which funds added shares in the latest reporting periods and how their positions changed over time.

  • What does "buy" mean in IMRX activity?

    "Buy" means an investor increased their reported position in IMRX compared to the prior reporting period. This reflects growing exposure to IMMUNEERING CORP - CLASS A (IMRX) rather than necessarily a brand-new position (though new positions also appear as buys when prior quantity was zero).

  • Is institutional interest in IMRX increasing?

    Institutional interest in IMRX can be assessed by comparing the number of tracked funds adding or increasing positions versus those trimming or exiting across the periods shown. A higher number of additions typically signals increasing participation among large filers, but it should be read alongside position sizes and the full table.

Related IMRX insights